Short- and longer-term all-cause mortality among SARS-CoV-2- infected persons and the pull-forward phenomenon in Qatar

Background: Risk of short- and long-term all-cause mortality after a primary SARS-CoV-2 infection is inadequately understood. Methods: A national, matched, retrospective cohort study was conducted in Qatar to assess the risk of all-cause mortality in the national cohort of people infected with SARS-CoV-2 compared with a reference national control cohort of uninfected persons. Associations were estimated using Cox proportional-hazards regression models. Results: Among unvaccinated persons, within 90 days after primary infection, adjusted hazard ratio (aHR) comparing incidence of death in the primary-infection cohort with the infection-naive cohort was 1.19 (95% CI: 1.02-1.39). The aHR was 1.34 (95% CI: 1.11-1.63) in persons more clinically vulnerable to severe COVID-19 and 0.94 (95% CI: 0.72-1.24) in those less clinically vulnerable to severe COVID-19. In subsequent follow-up, the aHR was 0.50 (95% CI: 0.37-0.68). The aHR was 0.41 (95% CI: 0.28-0.58) in months 3-7 after the primary infection and 0.76 (95% CI: 0.46-1.26) in subsequent months. The aHR was 0.37 (95% CI: 0.25-0.54) in persons more clinically vulnerable to severe COVID-19 and 0.77 (95% CI: 0.48-1.24) in those less clinically vulnerable to severe COVID-19. Among vaccinated persons, no evidence was found for differences in incidence of death in the primary-infection versus infection-naive cohorts, even among persons more clinically vulnerable to severe COVID-19. Conclusions: COVID-19 mortality in Qatar appears primarily driven by forward displacement of deaths of individuals with relatively short life expectancy and more clinically vulnerable to severe COVID-19. Vaccination negated the mortality displacement by preventing early deaths.

[1]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[2]  Z. Al-Aly,et al.  Long COVID after breakthrough SARS-CoV-2 infection , 2022, Nature Medicine.

[3]  Gheyath K Nasrallah,et al.  Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.

[4]  Gheyath K Nasrallah,et al.  Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.

[5]  Gheyath K Nasrallah,et al.  Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.

[6]  L. Abu-Raddad,et al.  Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar , 2022, The New England journal of medicine.

[7]  Gheyath K Nasrallah,et al.  Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[8]  L. Abu-Raddad,et al.  Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.

[9]  M. Hernán,et al.  Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.

[10]  L. Abu-Raddad,et al.  SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar , 2021, Scientific Reports.

[11]  J. Klausner,et al.  A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection , 2021, medRxiv.

[12]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[13]  Dmitri A. Jdanov,et al.  Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries , 2021, BMJ.

[14]  Gheyath K Nasrallah,et al.  SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar , 2021, Open forum infectious diseases.

[15]  L. Abu-Raddad,et al.  Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar , 2021, Emerging infectious diseases.

[16]  Gheyath K Nasrallah,et al.  SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals , 2021, iScience.

[17]  R. Bertollini,et al.  Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 , 2020, medRxiv.

[18]  R. Bertollini,et al.  Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic , 2020, Scientific Reports.

[19]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[20]  M. Weijenberg,et al.  The impact of heat waves and cold spells on mortality rates in the Dutch population. , 2001, Environmental health perspectives.